TABLE 3.
Clinical and pathologic factors of matched-patient cohort
| Factor | Sporadic (n = 98) | RA-UPS/MFH (n = 55) | p value |
|---|---|---|---|
| Sarcoma location | 0.129 | ||
| Head & neck | 10 (10.3) | 10 (18.2) | |
| Trunk | 54 (55.1) | 28 (49.1) | |
| Extremity | 27 (27.6) | 9 (16.4) | |
| Retroperitoneal | 7 (7.1) | 8 (14.5) | |
| Female | 55 (56.1) | 33 (60.0) | 0.642 |
| Median size (cm) | 6.0 | 6.0 | 0.460 |
| Deep | 68 (72.3) | 44 (81.5) | 0.212 |
| Median age (years) | 62.2 | 57.46 | 0.540 |
| Size ≥5 cm | 59 (60.8) | 29 (59.2) | 0.848 |
| Resection score | 0.532 | ||
| R0 | 76 (79.2) | 44 (80.0) | |
| R1 | 14 (14.6) | 8 (14.5) | |
| R2 | 3 (3.1) | 3 (5..5) | |
| Received chemotherapya | 22 (24.2) | 16 (29.1) | 0.547 |
| Received radiationb | 69 (71.1) | 12 (22.3) | < 0.001 |
RA, radiation-associated; UPS, undifferentiated pleomorphic sarcoma; MFH, malignant fibrous histiocytoma
a
Either adjuvant or neoadjuvant chemotherapy for sarcoma
b
Either pre- or postoperative radiation for sarcoma